Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus
Sentinel Lymph Node Sampling Versus Systematic Pelvic Lymphadenectomy on the Prognosis for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus Before Surgery: a Non-inferiority Randomized Controlled Trial
Sponsor: Chongqing University Cancer Hospital
Listed as NCT04276532, this NA trial focuses on Middle-high Risk Endometrial Cancer and Prognosis and remains ongoing. Sponsored by Chongqing University Cancer Hospital, it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting NA
-
Jun 2025 — Mar 2026 [monthly]
Active Not Recruiting NA
-
Mar 2025 — Jun 2025 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 7 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting NA
-
Apr 2023 — May 2024 [monthly]
Recruiting NA
-
Apr 2022 — Apr 2023 [monthly]
Recruiting NA
-
Sep 2021 — Apr 2022 [monthly]
Recruiting NA
-
Jan 2021 — Sep 2021 [monthly]
Recruiting NA
-
Nov 2020 — Jan 2021 [monthly]
Recruiting NA
-
Mar 2020 — Nov 2020 [monthly]
Recruiting NA
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chongqing University Cancer Hospital
- Fudan University
- Sun Yat-Sen University Cancer Center
- Tongji Hospital
- West China Second University Hospital
- Xiaojun Chen
For direct contact, visit the study record on ClinicalTrials.gov .